Norwest Venture Partners Hires Tiba Aynechi as General Partner on Healthcare Investment Team
PALO ALTO, Calif., January 12, 2022-- Norwest Venture Partners, a leading venture capital and growth equity investment firm, announced today that Tiba Aynechi, Ph. D., has joined the investment team as a general partner to lead its biotech practice. Tiba brings nearly two decades of life sciences research and investing experience, spanning various therapeutic areas and technology platforms. She joins Norwest from Novo Holdings A/S, where she served from 2010 to 2021, most recently as a senior partner. "I am excited for Tiba to join our team, having had the opportunity to work side by side with her for many years on the boards of Avalyn Pharma and iRhythm Technologies," said Casper de Clercq, general partner, Norwest Venture Partners. "Her investment track record building innovative companies will be valuable as we extend our focus into biotechnology with our newly raised fund." "Today, innovations in healthcare impact every facet of our lives  from AI and tech-enabled platforms to advances in biology and genomics," said Tiba Aynechi, general partner, Norwest Venture Partners. "Norwest has an impressive track record and I look forward to broadening our healthcare and biotech practice." During her 11 years at Novo Holdings A/S, Tiba invested in numerous companies and served on the boards of Aristea Therapeutics, Avalyn Pharma, Arcellx, Allievex, Cianna Medical (acquired by Merit Medical), iRhythm Technologies (IPO), MDLIVE (acquired by Cigna), Mirum Pharmaceuticals (IPO), Nkarta (IPO) and Spruce Biosciences (IPO). Tiba earned a doctoral degree from the Graduate Group in Biophysics at the University of California, San Francisco, where her research involved developing computational methods for drug discovery. She also earned a Bachelor's degree in Physics from the University of California, Irvine. Tiba is a published author of scientific articles and several book chapters in the area of rational drug design. Last month, Norwest announced the close of a $3 billion fund that will invest across consumer, enterprise and healthcare markets. With this fund, Norwest will expand into biotechnology in addition to investing in healthcare IT, healthcare services, pharma services and medical devices. Among the innovative companies in Norwest's portfolio are Avalyn Pharma, BillionToOne, Blue Cloud, Clever Care Health Plan, Excision Biotherapeutics, Kyo, Monogram Health, Mindful Health Solutions, Neocis, Omada Health, Onsite Dental, Robin, Route 92 Medical, Target RWE and TigerConnect. Norwest's healthcare exits include Basis (acquired by Intel), Capsugel (acquired by Lonza), Crossover Health (acquired by private equity), Devoro Medical (acquired by Boston Scientific), Health Catalyst (IPO), Intersect ENT (IPO), iCardiac (acquired by ERT), iRhythm Technologies (IPO), Misfit Wearables (acquired by Fossil), Silk Road Medical (IPO), Talkspace (SPAC), Telcare (acquired by BioTelemetry) and VisitPay (acquired by R1). About Norwest Venture Partners
Norwest is a leading venture and growth equity investment firm managing more than $12.5 billion in capital. Since its inception, Norwest has invested in more than 650 companies and currently partners with more than 200 companies in its venture and growth equity portfolio. The firm invests in early to late-stage businesses across a wide range of sectors with a focus on consumer, enterprise, and healthcare. The Norwest team offers a deep network of connections, operating experience, and a wide range of impactful services to help CEOs and founders scale their businesses. Norwest has offices in Palo Alto and San Francisco, with subsidiaries in India and Israel. For more information, please visit www.nvp.com. Follow Norwest on Twitter @NorwestVP. All brands, names, or trademarks mentioned in this document are the property of their respective owners.

Norwest Venture Partners Hires Tiba Aynechi as General Partner on Healthcare Investment Team

October 20, 2021 06:00 AM Eastern Daylight Time
SEATTLE--( BUSINESS WIRE )--Avalyn Pharma Inc., a biopharmaceutical company focused on development of improved therapies for life threatening pulmonary diseases, announced today that Marc Schneebaum has joined the company as Chief Financial Officer. “I am pleased to welcome Marc to Avalyn as our Chief Financial Officer,” said Dr. A. Bruce Montgomery, CEO of Avalyn. “We are preparing to advance our lead drug candidate, inhaled pirfenidone (AP01), into Phase 3 studies, with important implications for the Company’s growth and its strategic and operational needs. Marc’s broad experience in biopharma and other life science organizations, will be quite valuable as we transition to the later stages of development. His specific skills in financing and financial strategy, corporate strategy and business development will be particularly important.”
Most recently, Mr. Schneebaum was Senior Vice President and Chief Financial Officer of Madrigal Pharmaceuticals, Inc., where he leveraged Madrigal’s $60 million in liquidity sources as a new public company and thereafter financed over $600 million in equity capital in support of the company’s Phase 2 and Phase 3 clinical studies and corporate growth. Prior to Madrigal, Marc was Senior Vice President and Chief Financial Officer of Synta Pharmaceuticals, Inc., a company developing oncology drugs; President, Chief Executive Officer and a director of Predictive BioSciences, Inc., a commercial stage oncology diagnostics company; President, Chief Executive Officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company; Senior Vice President, Finance, Business Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis). Mr. Schneebaum was a Vice President at Alex. Brown & Sons Incorporated, a leading investment banking firm, where he participated in a variety of finance and strategic assignments, and he began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum served as a director of GenVec, Inc., a publicly-held biopharmaceutical company acquired by Intrexon Corporation, from 2007 to 2017, and as a director of several privately-held life science companies. Mr. Schneebaum earned his degree in Business Administration from the University of Maryland. “Avalyn’s innovative therapeutic for IPF may be a breakthrough for patients with this deadly disease,” said Mr. Schneebaum. “I am excited to join Avalyn at this pivotal juncture in development of its pipeline of therapeutics to treat severe respiratory diseases, and I look forward to working with Bruce and the Avalyn team to contribute to the Company’s growth and success.”
Clinical Need
Idiopathic pulmonary fibrosis (IPF) and other progressive, fibrosing lung diseases (PFILD) are characterized by increasing scarring, decline in lung function, reduced exercise capacity and quality of life, and are associated with early death despite approved therapies. Current treatments are limited to oral pirfenidone (Esbriet®) for IPF and oral nintedanib (Ofev®) for IPF and PFILD. Both medicines, while effective in slowing disease progression, are associated with significant adverse effects that limit dosing and their full potential for efficacy. While these medicines are an important first step to treat IPF and PFILD, a substantial unmet need remains for therapies with improved safety profiles and superior efficacy as either stand-alone or add-on combination. The Inhaled Advantage
Although oral pirfenidone has shown to slow disease progression in IPF and PFILD, it is a low potency drug requiring a large oral dose to achieve efficacious lung levels. Unfortunately, oral delivery results in first pass metabolism and blood levels which cause substantial adverse effects while providing limited lung dose levels. Avalyn’s AP01, a formulation of pirfenidone optimized for delivery via inhalation, results in approximately 1/15th the systemic exposure of oral pirfenidone, yet it delivers 35-fold higher peak exposure to the affected lung tissue compared to the oral drug. In a recent 91 patient study of two dose regimens of AP01, Avalyn demonstrated the potential of AP01 to improve both efficacy and safety over oral therapy. Specifically, during the first 24 weeks of the study, nausea and rash side effects commonly associated with oral pirfenidone were less frequent with AP01 and a dose response was shown in the change from baseline in forced vital capacity (FVC) with the high dose group, on average, exhibiting stable lung function. About Avalyn Pharma
Contacts

Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer

May 24, 2021 06:00 AM Eastern Daylight Time
SEATTLE--( BUSINESS WIRE )--Avalyn Pharma Inc., a biopharmaceutical company focused on development of improved therapies for life threatening pulmonary diseases, presented at the ISAM conference in Boise, Idaho today, the results of the 24 week data of a Phase I/II clinical study of two dose regimens of AP01 (a formulation of pirfenidone optimized for delivery via inhalation) in patients with idiopathic pulmonary fibrosis (IPF). Ninety-one patients with IPF were randomized to 50 mg once daily (n=46) or 100 mg twice daily (n=45), administered by an investigational eFlow® nebulizer (PARI Pharma GmbH). During the first 24 weeks, the high dose group had, on average, no loss of lung function as measured by forced vital capacity (FVC). The low dose group had a progressive loss of lung function. The differences in FVC between the two groups was statistically significant (p=0.049). AP01 was safe and well tolerated at both doses. Flu-like symptoms and GI adverse events most commonly attributed to oral pirfenidone were seen in less than 10% of patients treated with AP01. Adverse events with a frequency of greater that 10% were rash 18%, upper respiratory tract infection 18%, cough 24%. Most subjects have opted to continue in the 12 month extension. Longer term efficacy and safety data will be presented at an upcoming scientific meeting. “We are pleased by the efficacy and safety profile we have seen to date with aerosolized pirfenidone in 91 patients over 24 weeks. The six month FVC data is very promising as well as the overall safety profile to date,” said Dr. A. Bruce Montgomery, CEO of Avalyn Pharma. "Despite the 2014 approval of two oral antifibrotic therapies, IPF and other fibrotic lung diseases remain fatal disorders with substantial unmet need. We hope to confirm improved tolerability and long term efficacy with aerosolized pirfenidone in future Phase 3 trials.”
Clinical Need
IPF and other fibrotic lung diseases are characterized by progressive scarring, reduced exercise capacity and ultimate death from respiratory failure and/or co-morbidities. IPF treatments are relatively new, with the first and only approvals coming in 2014: oral pirfenidone (Esbriet®) and oral nintedanib (Ofev®). Both medicines, while effective in slowing disease progression are associated with significant adverse effects that limit dosing and their full potential for efficacy. While these medicines are an important first step to treat IPF, a substantial unmet need remains for therapies with improved safety profiles and superior efficacy as either stand-alone or add-on combination therapies in both IPF and other fibrotic lung diseases. The Inhaled Advantage
Although oral pirfenidone has shown to slow IPF disease progression, it is a low potency drug requiring a large oral dose to achieve efficacious lung levels. Unfortunately, oral delivery results in blood levels which cause substantial adverse effects and provides limited lung dose levels. In this Phase I/II 24 week study of AP01, we have demonstrated the potential of aerosolized pirfenidone to improve both efficacy and safety. About Avalyn Pharma
Contacts

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial

Avalyn Pharma Inc.
24.05.2021 - 19:31:31
Avalyn Pharma berichtet über eine statistisch signifikante Dosisreaktion mit aerosolisiertem Pirfenidon in einer idiopathischen Lungenfibrose-Studie. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung verbesserter Therapien für lebensbedrohliche Lungenerkrankungen konzentriert. Heute präsentierte es auf der ISAM-Konferenz in Boise, Idaho, die Ergebnisse der 24-wöchigen Daten einer klinischen Phase-I/II-Studie mit zwei Dosierungsschemata von AP01 (eine Formulierung von Pirfenidon, die für die Abgabe durch Inhalation optimiert ist) bei Patienten mit idiopathischer Lungenfibrose (IPF). 91 Patienten mit IPF erhielten randomisiert einmal täglich 50 mg (n=46) oder zweimal täglich 100 mg (n=45), verabreicht mit einem eFlow®-Zerstäuber (PARI Pharma GmbH). Während der ersten 24 Wochen hatte die Hochdosisgruppe im Durchschnitt keinen Verlust der Lungenfunktion, gemessen an der forcierten Vitalkapazität (FVC). Die niedrig dosierte Gruppe hatte einen progressiven Verlust der Lungenfunktion. Die Unterschiede in der FVC zwischen den beiden Gruppen waren statistisch signifikant (p=0,049). AP01 war bei beiden Dosen sicher und gut verträglich. Grippeähnliche Symptome und gastrointestinale Nebenwirkungen, die am häufigsten auf orales Pirfenidon zurückgeführt werden, wurden bei weniger als 10 % der mit AP01 behandelten Patienten beobachtet. Unerwünschte Ereignisse mit einer Häufigkeit von mehr als 10 % waren Hautausschlag 18 %, Infektion der oberen Atemwege 18 %, Husten 24 %. Die meisten Probanden haben sich dafür entschieden, die 12-monatige Verlängerung fortzusetzen. Langzeitdaten zur Wirksamkeit und Sicherheit werden auf einem bevorstehenden wissenschaftlichen Treffen vorgestellt. „Wir freuen uns über das Wirksamkeits- und Sicherheitsprofil, das wir bisher bei 91 Patienten über 24 Wochen mit aerosolisiertem Pirfenidon gesehen haben. Die sechsmonatigen FVC-Daten sind sehr vielversprechend, ebenso wie das bisherige allgemeine Sicherheitsprofil“, sagte Dr. A. Bruce Montgomery, CEO von Avalyn Pharma. „Trotz der Zulassung von zwei oralen antifibrotischen Therapien im Jahr 2014 bleiben IPF und andere fibrotische Lungenerkrankungen tödliche Erkrankungen mit erheblichem ungedecktem Bedarf. Wir hoffen, in zukünftigen Phase-3-Studien eine verbesserte Verträglichkeit und Langzeitwirksamkeit mit aerosolisiertem Pirfenidon bestätigen zu können.“
Klinischer Bedarf
IPF und andere fibrotische Lungenerkrankungen sind durch fortschreitende Narbenbildung, verminderte Belastbarkeit und endgültigen Tod durch Atemversagen und/oder Komorbiditäten gekennzeichnet. IPF-Behandlungen sind relativ neu. Die ersten und einzigen Zulassungen werden 2014 erteilt: orales Pirfenidon (Esbriet®) und orales Nintedanib (Ofev®). Beide Arzneimittel verlangsamen zwar das Fortschreiten der Krankheit, sind jedoch mit erheblichen Nebenwirkungen verbunden, die die Dosierung und ihr volles Wirksamkeitspotential einschränken. Während diese Arzneimittel ein wichtiger erster Schritt zur Behandlung von IPF sind, besteht nach wie vor ein erheblicher Bedarf an Therapien mit verbesserten Sicherheitsprofilen und überlegener Wirksamkeit als Einzel- oder Zusatzkombinationstherapien sowohl bei IPF als auch bei anderen fibrotischen Lungenerkrankungen. Der Vorteil von Inhalation
Obwohl gezeigt hat, dass orales Pirfenidon das Fortschreiten der IPF-Krankheit verlangsamt, ist es ein Medikament mit niedriger Wirksamkeit, das eine große orale Dosis benötigt, um wirksame Lungenspiegel zu erreichen. Leider führt die orale Verabreichung zu Blutspiegeln, die erhebliche nachteilige Auswirkungen haben und begrenzte Lungendosiswerte liefern. In dieser 24-wöchigen Phase I/II-Studie zu AP01 haben wir das Potenzial von aerosolisiertem Pirfenidon zur Verbesserung von Wirksamkeit und Sicherheit gezeigt. Über Avalyn Pharma
Weitere Informationen finden Sie auf www.Avalynpharma.com . Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab. Originalversion auf businesswire.com ansehen: https://www.businesswire.com/news/home/20210524005712/de/
@ businesswire.com

Avalyn Pharma Inc.

| AstraZeneca, Sanofi, Vectura Group plc, Avalyn Pharma, Mylan N.V., Quotient Sciences
Databridgemarketresearch.com added a new study on Inhalable Drugs Market Research Review 2018 that has been just made available providing an extensive knowledge and perceptions of the industry. In order to build a through future prospect for the Inhalable Drugs Market, the current and historical data has been gathered, classified and analyzed. Major industry experts and analysts examining the industry were interviewed to obtain the data validating through secondary research findings. Inhalable Drugs Market Report contains key drivers and Restraints of the market with their information and market competition situation among the vendors and company profile. Product picture, specification, classification, category are also mentioned. Comprehensively evaluates absolute scrutiny of the competitive landscape, covering value chain and key players. Inhalable drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 38.32 billion by 2028 and will grow at a CAGR of 5.65% in the above mentioned forecast period. Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-inhalable-drugs-market
The major players covered in the inhalable drugs market report are AstraZeneca, Sanofi, Vectura Group plc, Avalyn Pharma, Mylan N.V., Quotient Sciences, Alaxia, EffRx Pharmaceuticals SA, GlaxoSmithKline Plc, Merck & Co., Inc., TFF PHARMACEUTICALS, INC., Catalent, Inc, IRISYS, LLC, Teicos Pharma Ltd, Nelson Laboratories, LLC, Intertek Group plc, Mundipharma International, Pharmaxis Ltd., Boehringer Ingelheim International GmbH and Cipla Inc., among other domestic and global players. Global Inhalable Drugs Market Scope and Market Size
Inhalable drugs market is segmented on the basis of product type and application. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. On the basis of product type, the inhalable drugs market is segmented into aerosol, dry powder formulation and spray. The application segment of the inhalable drugs market is segmented into respiratory diseases and non-respiratory diseases. Respiratory diseases have further been segmented into asthma, chronic obstructive pulmonary disease (COPD), infectious diseases and other respiratory diseases. Competitive Landscape and Inhalable Drugs Market Share Analysis
Inhalable drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to inhalable drugs market. Inhalable drugs are broadly used for treating chronic diseases such as COPD, bronchospasm, and asthma and non-respiratory diseases such as diabetes and Parkinson’s disease. Medicines that one breathes directly into lungs are an essential part of treatment for the lungs. Various combinations of inhaled drugs are used to heal many lung diseases, counting asthma and chronic obstructive pulmonary diseases (COPD). The increasing prevalence of non-respiratory diseases such as Parkinson’s disease and diabetes is among the essential factors that intensify the inhalable drugs market’s growth and demand. The rising geriatric population and advancements in inhalable drug therapies are also contributing to rising in the global market over the forecast period of 2021 to 2028. Also, the growing popularity of the procedure owing to its advantages over the oral and parenteral drug administration such as direct injection into the body or bypassing the skin and mucous membranes is also enhancing the market’s growth. Likewise, the increasing prevalence of various respiratory diseases such as chronic obstructive pulmonary diseases (COPD), asthma, and cystic fibrosis are also lifting the market growth in the above-mentioned forecast period. The rising investment in research and growth activities associated with unmet medical needs will further accelerate the expansion of the inhalable drugs market and offer significant growth opportunities for the market in the forecast period of 2021 to 2028. For More Insights Get FREE Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-inhalable-drugs-market
However, the stringent regulations will curb the growth of the inhalable drugs market, whereas the easy availability of alternative therapy has the potential to challenge the development of the inhalable drugs market. This inhalable drugs market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on inhalable drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT– GET FREE COVID-19 SAMPLE@ https://www.databridgemarketresearch.com/covid-19-impact/global-inhalable-drugs-market
Inhalable Drugs Market Country Level Analysis
Inhalable drugs market is analyzed and market size insights and trends are provided by country, product type and application as referenced above. The countries covered in the  inhalable drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America. North America region leads the inhalable drugs market owing to the easy availability of advanced products and growing awareness programs by the government and major players within the region. Asia-Pacific is expected to expand at a significant growth rate over the forecast period of 2021 to 2028 because of the rising disposable income and escalating investment in the healthcare sector by various government and non-governmental bodies in this particular region. The country section of the inhalable drugs market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. Healthcare Infrastructure growth Installed base and New Technology Penetration
Inhalable drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for inhalable drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the inhalable drugs market. The data is available for historic period 2010 to 2019. About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Inhalable Drugs Market Booming Demand Leading To Exponential CAGR Growth By 2028 | AstraZeneca, Sanofi, Vectura Group plc, Avalyn Pharma, Mylan N.V., Quotient Sciences

Ciclofilin Pharmaceuticals

VentiRx Pharmaceuticals

Anadys Pharmaceuticals

Agouron Pharmaceuticals

Verus Pharmaceuticals

Cardeas Pharma

Gilead Sciences

Corus Pharma

Genentech

Aires Pharmaceuticals

Mpex Pharmaceuticals

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Biopharma Tech

Series A

Series B

Avalyn Pharma, fka Genoa Pharmaceuticals, is a pharmaceutical company committed to developing improved therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The company's lead program (Aerodone inhaled pirfenidone) is advancing towards the clinic for the treatment of IPF. The US FDA has granted the company orphan-drug designation of pirfenidone for treatment of IPF.

Name	Work History	Title	Status
Michael J. Kamdar	Ciclofilin Pharmaceuticals, VentiRx Pharmaceuticals, Anadys Pharmaceuticals, and Agouron Pharmaceuticals	Founder	Current
Richard G Vincent	Verus Pharmaceuticals	Founder	Current
Bruce Montgomery	Cardeas Pharma, Gilead Sciences, Corus Pharma, and Genentech	Chief Executive Officer	Current
Mark Surber	Aires Pharmaceuticals, and Mpex Pharmaceuticals	Chief Executive Officer	Former

Name	Michael J. Kamdar	Richard G Vincent	Bruce Montgomery	Mark Surber
Work History	Ciclofilin Pharmaceuticals, VentiRx Pharmaceuticals, Anadys Pharmaceuticals, and Agouron Pharmaceuticals	Verus Pharmaceuticals	Cardeas Pharma, Gilead Sciences, Corus Pharma, and Genentech	Aires Pharmaceuticals, and Mpex Pharmaceuticals
Title	Founder	Founder	Chief Executive Officer	Chief Executive Officer
Status	Current	Current	Current	Former

Wells Fargo Success Story

3M Success Story

Platform Overview

Avalyn Pharma

Executives

Avalyn Pharma Management Team

4 Team Members

Discover the right solution for your team